Cancer Registry Software Market Size, Share & Trends Analysis Report By Software (Standalone), By Deployment model (On-premise), By Component (Commercial), By End-use, By Region, And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within 3 Business Days
Cancer Biopsy Market Growth & Trends
The global cancer biopsy market size is expected to reach USD 51.61 billion by 2030, registering a CAGR of 8.11% from 2024 to 2030, according to a new report by Grand View Research, Inc. The advancement in molecular medicine has facilitated the creation of novel devices for the molecular characterization of cancers. As a result, the rising acceptance and approvals of liquid biopsies are anticipated to be significant driving forces behind the overall market growth.
Numerous emerging manufacturers are dedicated to developing instruments that can improve endoscopy-based cancer biopsies. For instance, in March 2023, BiBBInstruments AB, a Swedish company, established a strong presence in the cancer biopsy instruments market under the brand - EndoDrill. The company changed biopsy instruments that allow rapid and precise diagnosis of cancer patients related to existing biopsy instruments. Moreover, it offers biopsy instruments catering to core needles and flexible endoscopic biopsies. Such companies developing in the market are expected to upsurge the accessibility of cancer biopsy instruments.
The field of oncology-based genomic data analysis and personalized medicine is anticipated to witness lucrative prospects with the emergence of liquid biopsies. Regulatory bodies are actively backing the commercialization of these products and promoting their utilization in clinical settings due to the significant potential they offer. Liquid biopsy facilitates cancer detection through various body fluids, and the advancements in this technique have made it an appealing noninvasive approach for obtaining cancer biomaterials for diagnostic purposes.
The liquid biopsies segment is projected to experience rapid expansion in the upcoming years, driven by significant investments and strategic efforts from companies engaged in biopharmaceutical manufacturing and genomic data analysis. Emerging companies are showing a strong inclination towards forming partnerships with established industry participants like QIAGEN Bioinformatics, Fabric Genomics, Agilent Technologies, and SOPHiA Genetics. This collaborative trend is expected to further boost the overall market growth.
Cancer Biopsy Market Report Highlights
Cancer Biopsy Market Growth & Trends
The global cancer biopsy market size is expected to reach USD 51.61 billion by 2030, registering a CAGR of 8.11% from 2024 to 2030, according to a new report by Grand View Research, Inc. The advancement in molecular medicine has facilitated the creation of novel devices for the molecular characterization of cancers. As a result, the rising acceptance and approvals of liquid biopsies are anticipated to be significant driving forces behind the overall market growth.
Numerous emerging manufacturers are dedicated to developing instruments that can improve endoscopy-based cancer biopsies. For instance, in March 2023, BiBBInstruments AB, a Swedish company, established a strong presence in the cancer biopsy instruments market under the brand - EndoDrill. The company changed biopsy instruments that allow rapid and precise diagnosis of cancer patients related to existing biopsy instruments. Moreover, it offers biopsy instruments catering to core needles and flexible endoscopic biopsies. Such companies developing in the market are expected to upsurge the accessibility of cancer biopsy instruments.
The field of oncology-based genomic data analysis and personalized medicine is anticipated to witness lucrative prospects with the emergence of liquid biopsies. Regulatory bodies are actively backing the commercialization of these products and promoting their utilization in clinical settings due to the significant potential they offer. Liquid biopsy facilitates cancer detection through various body fluids, and the advancements in this technique have made it an appealing noninvasive approach for obtaining cancer biomaterials for diagnostic purposes.
The liquid biopsies segment is projected to experience rapid expansion in the upcoming years, driven by significant investments and strategic efforts from companies engaged in biopharmaceutical manufacturing and genomic data analysis. Emerging companies are showing a strong inclination towards forming partnerships with established industry participants like QIAGEN Bioinformatics, Fabric Genomics, Agilent Technologies, and SOPHiA Genetics. This collaborative trend is expected to further boost the overall market growth.
Cancer Biopsy Market Report Highlights
- In 2023, kits and consumables held the largest market share by product, and this dominance is projected to persist throughout the forecast period. The increased adoption of kits and consumables can be attributed to the notable shift from tumor biopsies to liquid biopsies.
- Tissue biopsies remain a fundamental aspect of the biopsy process and are widely utilized across various diagnostic applications. Furthermore, tumor biopsies are primarily employed for individual-level diagnosis and monitoring the efficacy of ongoing oncology treatments.
- In terms of application, breast cancer dominated the global market in 2023 and is expected to maintain its lead throughout the forecast period. Open surgical biopsy remains a reference standard for evaluating patients with suspicious breast lesions, owing to its established accuracy in diagnosing such conditions. Consequently, this segment's revenue is bolstered by its proven efficacy in breast lesion diagnosis.
- North America held the largest revenue share in 2023 owing to the concentrated pool of active organizations and cancer foundations. The strong network of government organizations and private cancer foundations in the U.S. has made significant contributions to the regional revenue generation capacity.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. CANCER REGISTRY SOFTWARE MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Cancer Registry Software Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
CHAPTER 4. CANCER REGISTRY SOFTWARE MARKET: SOFTWARE ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Cancer Registry Software Market: Software Movement Analysis, 2023 & 2030 (USD Million)
4.3. Standalone
4.3.1. Standalone Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Integrated
4.4.1. Integrated Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. CANCER REGISTRY SOFTWARE MARKET: DEPLOYMENT MODEL ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Cancer Registry Software Market: Deployment Model Movement Analysis, 2023 & 2030 (USD Million)
5.3. On-premise
5.3.1. On-premise Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Cloud Based
5.4.1. Cloud Based Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. CANCER REGISTRY SOFTWARE MARKET: COMPONENT ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Cancer Registry Software Market: Component Movement Analysis, 2023 & 2030 (USD Million)
6.3. Commercial
6.3.1. Commercial Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Public
6.4.1. Public Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. CANCER REGISTRY SOFTWARE MARKET: END-USE ESTIMATES & TREND ANALYSIS
7.1. Segment Dashboard
7.2. Cancer Registry Software Market: End-use Movement Analysis, 2023 & 2030 (USD Million)
7.3. Government & Third Party
7.3.1. Government & Third-Party Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Private Payers
7.4.1. Private Payers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Hospital & Medical Practice
7.5.1. Hospital & Medical Practice Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Pharma Biotech & Medical Device Companies
7.6.1. Pharma Biotech & Medical Device Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7. Research Institutes
7.7.1. Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 8. CANCER REGISTRY SOFTWARE MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
8.1. Cancer Registry Software Market Share, By Region, 2023 & 2030, USD Million
8.2. North America
8.2.1. North America Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.2. U.S.
8.2.2.1. U.S. Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.3. Canada
8.2.3.1. Canada Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.4. Mexico
8.2.4.1. Mexico Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3. Europe
8.3.1. Europe Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.2. UK
8.3.2.1. UK Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.3. Germany
8.3.3.1. Germany Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.4. France
8.3.4.1. France Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.5. Italy
8.3.5.1. Italy Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.6. Spain
8.3.6.1. Spain Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.7. Denmark
8.3.7.1. Denmark Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.8. Sweden
8.3.8.1. Sweden Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.9. Norway
8.3.9.1. Norway Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4. Asia Pacific
8.4.1. Asia Pacific Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.2. Japan
8.4.2.1. Japan Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.3. China
8.4.3.1. China Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.4. India
8.4.4.1. India Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.5. Australia
8.4.5.1. Australia Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.6. South Korea
8.4.6.1. South Korea Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.7. Thailand
8.4.7.1. Thailand Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. Latin America
8.5.1. Latin America Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.2. Brazil
8.5.2.1. Brazil Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.3. Argentina
8.5.3.1. Argentina Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6. Middle East and Africa
8.6.1. Middle East and Africa Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.2. South Africa
8.6.2.1. South Africa Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.3. Saudi Arabia
8.6.3.1. Saudi Arabia Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.4. UAE
8.6.4.1. UAE Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.5. Kuwait
8.6.5.1. Kuwait Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 9. COMPETITIVE LANDSCAPE
9.1. Recent Developments & Impact Analysis by Key Market Participants
9.2. Company Categorization
9.3. Company Heat Map Analysis
9.4. Company Profiles
9.4.1. Elekta
9.4.1.1. Participant’s Overview
9.4.1.2. Financial Performance
9.4.1.3. Product Benchmarking
9.4.1.4. Recent Developments/ Strategic Initiatives
9.4.2. Oracle
9.4.2.1. Participant’s Overview
9.4.2.2. Financial Performance
9.4.2.3. Product Benchmarking
9.4.2.4. Recent Developments/ Strategic Initiatives
9.4.3. ONCO, Inc.
9.4.3.1. Participant’s Overview
9.4.3.2. Financial Performance
9.4.3.3. Product Benchmarking
9.4.3.4. Recent Developments/ Strategic Initiatives
9.4.4. IBM
9.4.4.1. Participant’s Overview
9.4.4.2. Financial Performance
9.4.4.3. Product Benchmarking
9.4.4.4. Recent Developments/ Strategic Initiatives
9.4.5. MCKESSON CORPORATION
9.4.5.1. Participant’s Overview
9.4.5.2. Financial Performance
9.4.5.3. Product Benchmarking
9.4.5.4. Recent Developments/ Strategic Initiatives
9.4.6. Conduent, Inc.
9.4.6.1. Participant’s Overview
9.4.6.2. Financial Performance
9.4.6.3. Product Benchmarking
9.4.6.4. Recent Developments/ Strategic Initiatives
9.4.7. Ordinate Corporation
9.4.7.1. Participant’s Overview
9.4.7.2. Financial Performance
9.4.7.3. Product Benchmarking
9.4.7.4. Recent Developments/ Strategic Initiatives
9.4.8. Volpara Health Limited
9.4.8.1. Participant’s Overview
9.4.8.2. Financial Performance
9.4.8.3. Product Benchmarking
9.4.8.4. Recent Developments/ Strategic Initiatives
9.4.9. Health Catalyst
9.4.9.1. Participant’s Overview
9.4.9.2. Financial Performance
9.4.9.3. Product Benchmarking
9.4.9.4. Recent Developments/ Strategic Initiatives
9.4.10. Rocky Mountain Cancer Data Systems (RMCDS) (University of Utah Health)
9.4.10.1. Participant’s Overview
9.4.10.2. Financial Performance
9.4.10.3. Product Benchmarking
9.4.10.4. Recent Developments/ Strategic Initiatives
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. CANCER REGISTRY SOFTWARE MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Cancer Registry Software Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
CHAPTER 4. CANCER REGISTRY SOFTWARE MARKET: SOFTWARE ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Cancer Registry Software Market: Software Movement Analysis, 2023 & 2030 (USD Million)
4.3. Standalone
4.3.1. Standalone Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Integrated
4.4.1. Integrated Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. CANCER REGISTRY SOFTWARE MARKET: DEPLOYMENT MODEL ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Cancer Registry Software Market: Deployment Model Movement Analysis, 2023 & 2030 (USD Million)
5.3. On-premise
5.3.1. On-premise Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Cloud Based
5.4.1. Cloud Based Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. CANCER REGISTRY SOFTWARE MARKET: COMPONENT ESTIMATES & TREND ANALYSIS
6.1. Segment Dashboard
6.2. Cancer Registry Software Market: Component Movement Analysis, 2023 & 2030 (USD Million)
6.3. Commercial
6.3.1. Commercial Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Public
6.4.1. Public Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. CANCER REGISTRY SOFTWARE MARKET: END-USE ESTIMATES & TREND ANALYSIS
7.1. Segment Dashboard
7.2. Cancer Registry Software Market: End-use Movement Analysis, 2023 & 2030 (USD Million)
7.3. Government & Third Party
7.3.1. Government & Third-Party Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Private Payers
7.4.1. Private Payers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Hospital & Medical Practice
7.5.1. Hospital & Medical Practice Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Pharma Biotech & Medical Device Companies
7.6.1. Pharma Biotech & Medical Device Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7. Research Institutes
7.7.1. Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 8. CANCER REGISTRY SOFTWARE MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
8.1. Cancer Registry Software Market Share, By Region, 2023 & 2030, USD Million
8.2. North America
8.2.1. North America Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.2. U.S.
8.2.2.1. U.S. Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.3. Canada
8.2.3.1. Canada Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.4. Mexico
8.2.4.1. Mexico Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3. Europe
8.3.1. Europe Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.2. UK
8.3.2.1. UK Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.3. Germany
8.3.3.1. Germany Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.4. France
8.3.4.1. France Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.5. Italy
8.3.5.1. Italy Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.6. Spain
8.3.6.1. Spain Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.7. Denmark
8.3.7.1. Denmark Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.8. Sweden
8.3.8.1. Sweden Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.9. Norway
8.3.9.1. Norway Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4. Asia Pacific
8.4.1. Asia Pacific Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.2. Japan
8.4.2.1. Japan Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.3. China
8.4.3.1. China Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.4. India
8.4.4.1. India Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.5. Australia
8.4.5.1. Australia Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.6. South Korea
8.4.6.1. South Korea Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.7. Thailand
8.4.7.1. Thailand Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. Latin America
8.5.1. Latin America Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.2. Brazil
8.5.2.1. Brazil Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.3. Argentina
8.5.3.1. Argentina Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6. Middle East and Africa
8.6.1. Middle East and Africa Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.2. South Africa
8.6.2.1. South Africa Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.3. Saudi Arabia
8.6.3.1. Saudi Arabia Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.4. UAE
8.6.4.1. UAE Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.5. Kuwait
8.6.5.1. Kuwait Cancer Registry Software Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 9. COMPETITIVE LANDSCAPE
9.1. Recent Developments & Impact Analysis by Key Market Participants
9.2. Company Categorization
9.3. Company Heat Map Analysis
9.4. Company Profiles
9.4.1. Elekta
9.4.1.1. Participant’s Overview
9.4.1.2. Financial Performance
9.4.1.3. Product Benchmarking
9.4.1.4. Recent Developments/ Strategic Initiatives
9.4.2. Oracle
9.4.2.1. Participant’s Overview
9.4.2.2. Financial Performance
9.4.2.3. Product Benchmarking
9.4.2.4. Recent Developments/ Strategic Initiatives
9.4.3. ONCO, Inc.
9.4.3.1. Participant’s Overview
9.4.3.2. Financial Performance
9.4.3.3. Product Benchmarking
9.4.3.4. Recent Developments/ Strategic Initiatives
9.4.4. IBM
9.4.4.1. Participant’s Overview
9.4.4.2. Financial Performance
9.4.4.3. Product Benchmarking
9.4.4.4. Recent Developments/ Strategic Initiatives
9.4.5. MCKESSON CORPORATION
9.4.5.1. Participant’s Overview
9.4.5.2. Financial Performance
9.4.5.3. Product Benchmarking
9.4.5.4. Recent Developments/ Strategic Initiatives
9.4.6. Conduent, Inc.
9.4.6.1. Participant’s Overview
9.4.6.2. Financial Performance
9.4.6.3. Product Benchmarking
9.4.6.4. Recent Developments/ Strategic Initiatives
9.4.7. Ordinate Corporation
9.4.7.1. Participant’s Overview
9.4.7.2. Financial Performance
9.4.7.3. Product Benchmarking
9.4.7.4. Recent Developments/ Strategic Initiatives
9.4.8. Volpara Health Limited
9.4.8.1. Participant’s Overview
9.4.8.2. Financial Performance
9.4.8.3. Product Benchmarking
9.4.8.4. Recent Developments/ Strategic Initiatives
9.4.9. Health Catalyst
9.4.9.1. Participant’s Overview
9.4.9.2. Financial Performance
9.4.9.3. Product Benchmarking
9.4.9.4. Recent Developments/ Strategic Initiatives
9.4.10. Rocky Mountain Cancer Data Systems (RMCDS) (University of Utah Health)
9.4.10.1. Participant’s Overview
9.4.10.2. Financial Performance
9.4.10.3. Product Benchmarking
9.4.10.4. Recent Developments/ Strategic Initiatives
